The global eosinophilic esophagitis treatment market is anticipated to grow at a considerable CAGR of 6.4% during the forecast period (2022-2028). The Increasing prevalence of eosinophilic esophagitis across the globe is one of the prime factors affecting and driving the market for eosinophilic esophagitis treatment. According to the information by the National Institutes of Health (NIH), the Eosinophilic esophagitis incidence increased from 0.01 % in 1995 to 3.16 % per 100.000 inhabitants in 2019. Eosinophilic esophagitis is considered a chronic immune disorder of the gastrointestinal system in which large numbers of eosinophils (a specific type of white blood cell) are present in the esophagus. Symptoms frequently associated with eosinophilic esophagitis include food impaction, dysphagia, and allergic disorders such as bronchial asthma.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/eosinophilic-esophagitis-treatment-market
Moreover, to gain on the opportunity key players operating in the global eosinophilic esophagitis treatment market had been adopting strategies such as new launches to achieve major market share. For instance, in August 2019, Astrazeneca had set forth that the company had received the US Food and Drug Administration (FDA) approval for Orphan Drug Designation (ODD) to Fasenra (benralizumab) for the treatment of eosinophilic esophagitis (EoE).
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
o By Product
o By Diagnosis
o By Treatment
- Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
- Competitive Landscape- AstraZeneca, Bristol-Myers Squibb, Novartis AG, Regeneron Pharmaceuticals, Inc., and Teva Pharmaceuticals Industries Ltd.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
- Who is the leader in the market?
- How are players addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Eosinophilic Esophagitis Treatment Market Report Segment
By Product
- Budesonide Oral Suspension
- Fluticasone ODT
- Mepolizumab
- Reslizumab
- Benralizumab
- Others
By Diagnosis
- Upper Endoscopy
- Esophagus Biopsy
- Blood Tests
By Treatment
- Dietary Therapy
- Medication
- Dilation
A full report of Eosinophilic Esophagitis Treatment Market is available at: https://www.omrglobal.com/industry-reports/eosinophilic-esophagitis-treatment-market
Eosinophilic Esophagitis Treatment Market– Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- Adare Pharmaceuticals, Inc.
- Allakos, Inc.
- Astrazeneca
- Axcan Pharma, Inc.
- Bristol-Myers Squibb
- Celgene Corp.
- Ception Therapeutics Inc.
- Falk Pharma Gmbh
- DBV Technologies
- Hikma Pharmaceuticals Plc
- Novartis AG
- Perrigo Co. Plc
Reasons to Buying From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
